PMID- 22431535
OWN - NLM
STAT- MEDLINE
DCOM- 20120504
LR  - 20211021
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 137
IP  - 4
DP  - 2012 Apr
TI  - HER2 amplification in gastroesophageal adenocarcinoma: correlation of two 
      antibodies using gastric cancer scoring criteria, H score, and digital image 
      analysis with fluorescence in situ hybridization.
PG  - 583-94
LID - 10.1309/AJCPXQVS6YGHPDCY [doi]
AB  - We assessed 103 resected gastroesophageal adenocarcinomas for HER2 amplification 
      by fluorescence in situ hybridization (FISH) and 2 commercial immunohistochemical 
      assays. Of 103, 30 (29%) were FISH-amplified. Both immunohistochemical assays had 
      greater than 95% concordance with FISH. However, as a screening test for FISH 
      amplification, the Ventana Medical Systems (Tucson, AZ) 4B5 antibody demonstrated 
      superior sensitivity (87%) compared with the DAKO (Carpinteria, CA) A0485 (70%). 
      Of the cases, 28 were immunohistochemically 3+ or immunohistochemically 
      2+/FISH-amplified with the 4B5 assay compared with only 22 cases with the A0485 
      assay, representing a large potential difference in patient eligibility for 
      anti-HER2 therapy. Cases with low-level FISH amplification (HER2/CEP17, 2.2-4.0) 
      express lower levels of HER2 protein compared with cases with high-level 
      amplification (HER2/CEP17, >/=4.0), raising the possibility of a differential 
      response to anti-HER2 therapy. The H score and digital image analysis may have a 
      limited role in improving HER2 test performance.
FAU - Radu, Oana M
AU  - Radu OM
AD  - Department of Pathology, University of Pittsburgh School of Medicine, PA 15213, 
      USA.
FAU - Foxwell, Tyler
AU  - Foxwell T
FAU - Cieply, Kathleen
AU  - Cieply K
FAU - Navina, Sarah
AU  - Navina S
FAU - Dacic, Sanja
AU  - Dacic S
FAU - Nason, Katie S
AU  - Nason KS
FAU - Davison, Jon M
AU  - Davison JM
LA  - eng
GR  - K07 CA151613/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/genetics/*metabolism/pathology
MH  - Aged
MH  - Aged, 80 and over
MH  - Esophageal Neoplasms/genetics/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Stomach Neoplasms/genetics/*metabolism/pathology
PMC - PMC4086745
MID - NIHMS597551
EDAT- 2012/03/21 06:00
MHDA- 2012/05/05 06:00
PMCR- 2014/07/08
CRDT- 2012/03/21 06:00
PHST- 2012/03/21 06:00 [entrez]
PHST- 2012/03/21 06:00 [pubmed]
PHST- 2012/05/05 06:00 [medline]
PHST- 2014/07/08 00:00 [pmc-release]
AID - 137/4/583 [pii]
AID - 10.1309/AJCPXQVS6YGHPDCY [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2012 Apr;137(4):583-94. doi: 10.1309/AJCPXQVS6YGHPDCY.